Immatics (IMTX) Projected to Post Quarterly Earnings on Thursday

Immatics (NASDAQ:IMTX) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $16.16 million for the quarter.

Immatics Stock Up 2.6 %

Shares of NASDAQ:IMTX opened at $5.11 on Wednesday. Immatics has a 12 month low of $4.06 and a 12 month high of $13.77. The company’s 50-day moving average price is $5.16 and its two-hundred day moving average price is $7.80. The firm has a market cap of $609.91 million, a P/E ratio of -7.74 and a beta of 0.83.

Analyst Upgrades and Downgrades

IMTX has been the topic of a number of research reports. The Goldman Sachs Group upgraded shares of Immatics to a “strong-buy” rating in a research report on Monday, November 25th. Bank of America cut their target price on shares of Immatics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.67.

Institutional Trading of Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE lifted its position in Immatics (NASDAQ:IMTX) by 166.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,575 shares of the company’s stock after acquiring an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 at the end of the most recent quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.